Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil and Glycemic Response in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Open cardiac surgery through sternotomy approach (coronary artery bypass, valve surgery, and any other open heart surgeries)~* Surgery with use of cardiopulmonary bypass~* Patients over 18 years of age~* Both female and male genders~* All races~Exclusion Criteria:~* Minimally invasive heart surgery through thoracotomy approach~* Patients receiving regional analgesia such as intrathecal morphine~* Patients undergoing procedures under deep hypothermic circulatory arrest~* Patients with active infections such as acute infective endocarditis~* Emergency surgery~* Patients undergoing transplantations and ventricular assist device insertion~* Patients on any mechanical circulatory support preoperatively~* Patient's refusal~* Allergy to remifentanil~* Positive pregnancy test~* Morbid obesity~* End stage liver and kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remifentanil group (Type: EXPERIMENTAL): Half of subjects enrolled will be randomized to the remifentanil group
- Fentanyl group (Type: ACTIVE_COMPARATOR): Half of subjects enrolled will be randomized to the fentanyl group

Based on this trial design, predict the completion outcome and termination type (if applicable).